Results 201 to 210 of about 28,620 (235)

CYP2C19 gene polymorphism in Ningxia

Pharmacological Reports, 2023
Poor metabolizer (PM) status of CYP2C19 can be a predisposing factor for developing gastric cancer in H. pylori-infected patients. It is unclear whether PM status of CYP2C19 can also be a potential factor for H.pylori infection in healthy people.We used high-throughput sequencing to detect single nucleotide polymorphisms (SNPs) at just three loci ...
Zhen Yang, Yunqian Xie, Daya Zhang, Yan Zou, Ximei Li, Runxiang Chen, Xiaodong Zhang, Shiju Chen, Feihu Bai   +8 more
openaire   +2 more sources

Identification of New Human CYP2C19 Alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian Poor Metabolizer of Mephenytoin

The Journal of Pharmacology and Experimental Therapeutics, 1998
A genetic polymorphism in the metabolism of the anticonvulsant drug S-mephenytoin has been attributed to defective CYP2C19 alleles. This genetic polymorphism displays large interracial differences with the poor metabolizer (PM) phenotype representing 2-5% of Caucasian and 13-23% of Oriental populations.
G C, Ibeanu, J A, Goldstein, U, Meyer, S, Benhamou, C, Bouchardy, P, Dayer, B I, Ghanayem, J, Blaisdell   +7 more
openaire   +2 more sources

Effects of Allicin on CYP2C19 and CYP3A4 Activity in Healthy Volunteers With Different CYP2C19 Genotypes

European Journal of Clinical Pharmacology, 2009
To investigate the interaction between allicin and omeprazole and to observe the effects of allicin on CYP2C19 and CYP3A4 activity in healthy Chinese male volunteers with different CYP2C19 genotypes.Eighteen subjects (six CYP2C19*1/CYP2C19*1, four CYP2C19*1/CYP2C19*2, two CYP2C19*1/ CYP2C19*3, and six CYP2C19*2/ CYP2C19*2) were enrolled in a two-phase ...
Zhao-Qian Liu, Dong Guo, Dong-Li Hu
exaly   +3 more sources

Clopidogrel Inhibits CYP2C19-Dependent Hydroxylation of Omeprazole Related to CYP2C19 Genetic Polymorphisms

Journal of Clinical Pharmacology, 2009
This study explores the impact of clopidogrel on the pharmacokinetics of omeprazole related to CYP2C19 genetic polymorphisms. Twelve healthy volunteers (6 CYP2C19*1/*1, 5 CYP2C19*2/*2, and 1 CYP2C19*2/*3) are enrolled in a 2‐phase randomized crossover trial.
H H Zhou, L S Wang
exaly   +3 more sources

Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*

Clinical Pharmacology & Therapeutics, 1995
The reversible monoamine oxidase A inhibitor moclobemide was given in single (300 mg) and multiple doses (600 mg/day) to 11 male and four female healthy volunteers (age range, 23 to 27) who were either poor metabolizers of S-mephenytoin (n = 7) or extensive metabolizers of S-mephenytoin (n = 8). All were extensive metabolizers of sparteine.
L F, Gram, T W, Guentert, S, Grange, K, Vistisen, K, Brøsen   +4 more
openaire   +2 more sources

Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole

Molecular Biology Reports, 2011
To relate the pharmacokinetics of orally administered lansoprazole in healthy adult Jordanian men with CYP2C19 polymorphisms and to determine the percentage of CYP2C19 polymorphism in Jordanian population and the allelic frequency of CYP2C19*2 and CYP2C19*3.
Imad, Zalloum, Nancy, Hakooz, Tawfiq, Arafat   +2 more
openaire   +2 more sources

Assessment of CYP2C19 Genetic Polymorphisms in a Korean Population Using a Simultaneous Multiplex Pyrosequencing Method to Simultaneously Detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 Alleles

Journal of Clinical Pharmacy and Therapeutics, 2010
J -Y Park, J-Y Park
exaly   +2 more sources

The CYP2C19 Enzyme Polymorphism

Pharmacology, 2000
The genetic test is gradually replacing probe drugs as the primary tool for screening populations for the CYP2C19 polymorphism. A full appreciation for the clinical and toxicological relevance of this genetic variation is presently limited. Further research is needed in several areas.
openaire   +2 more sources

Clopidogrel, CYP2C19, and a Black Box

The Journal of Clinical Pharmacology, 2013
AbstractIt has been presumed that CYP2C19 has a major role in the metabolism of clopidogrel. This presumption has been based on in vitro drug metabolism studies using microsomes from baculovirus infected insect cells (BD‐Supersomes™). If clopidogrel were primarily a CYP2C19 substrate, a drug/drug interaction with CYP2C19 inhibitors, such as proton pump
Neville F, Ford, Dirk, Taubert
openaire   +2 more sources

Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes

Xenobiotica, 2010
The objective of this study was to investigate the interaction between glycyrrhizin and omeprazole and observe the effects of glycyrrhizin on CYP2C19 and CYP3A4 activities in healthy Chinese male volunteers with different CYP2C19 genotypes. Eighteen healthy subjects (six CYP2C19*1/*1, five CYP2C19*1/*2, one CYP2C19*1/*3, five CYP2C19*2/*2 and one ...
J-H, Tu, D-L, Hu, L-L, Dai, Y, Sun, L, Fan, M, Zhang, Z-R, Tan, Y, Chen, Z, Li, H-H, Zhou   +9 more
openaire   +2 more sources